Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of ENTA is 19 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell